

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3040081

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JANSSEN PHARMACEUTICA NV	07/24/2012
RECEIVING PARTY DATA	
Name:	JANSSEN R&D IRELAND
Street Address:	EASTGATE VILLAGE, EASTGATE
City:	LITTLE ISLAND, CO CORK
State/Country:	IRELAND
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14118527
CORRESPONDENCE DATA	
Fax Number:	(732)846-6630
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	732-524-2543
Email:	mturner5@its.jnj.com
Correspondent Name:	BERNARD F. PLANTZ
Address Line 1:	JOHNSON & JOHNSON
Address Line 2:	ONE JOHNSON & JOHNSON PLAZA
Address Line 4:	NEW BRUNSWICK, NEW JERSEY 08933
ATTORNEY DOCKET NUMBER:	TIP0252USPCT
NAME OF SUBMITTER:	MARGARET TURNER, PATENT PARALEGAL
SIGNATURE:	/Margaret Turner/
DATE SIGNED:	09/26/2014
Total Attachments: 1	
source=JanssenPharmNV_to_JanssenRDIreland#page1.tif	

General Assignment

WHEREAS, **Janssen Pharmaceutica NV**, having its place of business at Turnhoutseweg 30, 2340 Beerse, Belgium (hereinafter called "Assignor"), is the owner of certain new and useful inventions relating to

**QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
AND FURTHER DISEASES**

for which on 18 May 2011, European Patent Application no. 11166538.6 was filed at the European Patent Office;

WHEREAS, **Janssen R&D Ireland**, having its place of business at Eastgate Village, Eastgate, Little Island, Co Cork, Ireland (hereinafter called "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to both said Assignees in equal shares its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignees, their successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made; and that Assignees herewith accept said assignment and transfer.

Assignor and Assignees agree that this general assignment shall be effective from 18 May 2011.

IN TESTIMONY WHEREOF, Assignor and Assignees hereunto set their hands and seal.


For Janssen Pharmaceutica NV



.....
Luc Quaghebeur

Date : 24 July 2012

For Janssen R&D Ireland



Frank Daelémans

Date : 24 July 2012